Sovremennoe lechenie psoriaticheskogo artrita


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analysis of current approaches to the drug therapy of psoriatic arthritis is performed. It is stated that the main goal of treatment is the achievement of disease remission or minimal activity of its manifestations ( arthritis, spondylitis, enthesitis, dactylitis, psoriasis); other goals include slowing of radiographic progression, increasing in life expectancy and improving the quality of life of patients, reducing the risk of comorbid diseases. The approaches to the treatment of psoriatic arthritis with the use of non-steroidal anti-inflammatory drugs, intra-articular injections of glucocorticoids, disease-modifying anti-rheumatic drugs, and genetically engineered biological agents are considered. Attention is paid to the fact that methotrexate has the most favorable ratio of efficacy and tolerability The article considers the currently available information on the potentials and prospects of the use of drugs based on monoclonal antibodies: tumor necrosis factor inhibitors and other interleukins in the treatment of psoriatic arthritis.

Full Text

Restricted Access

About the authors

T. V Korotaeva

Email: tatianakorotaeva@gmail.com

References

  1. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment// Ann. Rheum. Dis. - 2010 - Vol. 69(1). - P. 48-53.
  2. Gladman D.D. Mortalityinpsoriaticarthritis//Clin. Exp. Rheumatol. - 2008. - Vol. 26(Suppl. 51). -P. 62-5.
  3. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies// Ann. Rheum. Dis. - 2012. - Vol. 71. - P. 4-12.
  4. Mease P.J. Measures of Psoriatic Arthritis. Arthritis Care & Research. 2011;11(63):64-85.
  5. Borer J.S., Simon L.S. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance // Arthritis Res. Ther. - 2005. - Vol. 7(Suppl. 4). - P. 14-22.
  6. Kivitz A.J., Espinoza L.R., Sherrer Y.R., et al. A comparison of the eficacy and safety of cele-coxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis //Semin. Arthritis Rheum. - 2007. -Vol. 37. - P. 164-73.
  7. Soriano E., McHugh N. Therapies for peripheral joint disease in psoriatic arthritis. A systematic Review. J Rheum 2006;33:1-7.
  8. Eder L., Chandran V., Ueng J., et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis // Rheumatology (Oxford). -2010. - Vol. 49(7). - P. 1367-73.
  9. Saviola G., Abdi Ali L., Shams Eddin S., et al. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-monthopen randomizedpilot study//Rheumatology (Oxford). - 2007. - Vol. 46(6). -P. 994-98.
  10. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis // J. Am. Acad. Dermatol. - 2009. - Vol. 61. - P. 451-85.
  11. Pathirana D., Ormerod A.D., Saigag P., et al. European S3-guidelines on systemic treatment of psoriasis vulgaris // J. Eur. Acad. Dermatol. Venereol. - 2009. - P. 23. - P. 1-70.
  12. Ravindran V, Scott D.L., Choy E.H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis // Ann. Rheum. Dis. - 2008.- Vol. 67. - P. 855-59.
  13. Ash Z, Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis // Ann. Rheum. Dis. -2012. -Vol. 71. - P. 319-26.
  14. Gladman D., Mease P., Choy E., et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT // Arthritis Res. Ther. -2010. -Vol. 12(3). - P. 113.
  15. Fraser A.D., van Kuijk A.W.R., Westhovens R., et al. A randomized, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis // Ann. Rheum. Dis. - 2005. - Vol. 64. - P. 859-64.
  16. Abu-Shakra M., Gladman D.D., Thorne J.C., et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome // J. Rheum. - 1995. - Vol. 2. - P. 241-45.
  17. Black R.L., O'Brien W.M., Vanscott E.J., et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients // JAMA. -1964. - Vol. 189. - P. 743-47.
  18. Baranauskaite A., Raffayov H., Kungurov N., et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexatenaive patients: the RESPOND study // Ann. Rheum. Dis. - 2012. - Vol. 71(4). - P. 541-48.
  19. Espinoza L.R., Zakraoui L., Espinoza L.R. Psoriatic arthritis: clinical response and side effects to Methotrexate therapy// J. Rheum. - 1992. -Vol. 19. - P. 872-77.
  20. Combe B., Goupille P., Hamilton T.A., et al. Sulfasalazine in psoriatic arthritis: a randomized, multicenter, placebo - controlled study // Br. J. Rheum. - 1996. - Vol. 35. - P. 664-68.
  21. Salvarani C., Macchioni P., Olivieri I., et al. A Comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis // J. Rheum. - 2001. - Vol. 28. -P. 2274-82.
  22. Van Denderen J.C. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis // Ann. Rheum. Dis. - 2005. - Vol. 64(12). -P. 1761-64.
  23. Cuchacovich M., Soto L. Leflunomide decreases joint erosion and induces reparative changes in a patients with psoriatic arthritis // Ann. Rheum. Dis. - 2001. - Vol. 60. - P. 913-23.
  24. Kaltwasser J.P., Nash P., Gladman D.D., et al. Treatment of psoriatic arthritis study group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multionational, double-blind, randomized, placebocontrolled clinical trial// Arthr. Rheum. - 2004. - Vol. 50. - P. 1939-50.
  25. Macchioni P., Boiardi L., Cremonesi T., et al. The relationship between serum-soluble interleuikin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporine-A //Rheum. Int. - 1998. - Vol. 18. - P. 3327-53.
  26. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies// Ann. Rheum. Dis. - 2012. - Vol. 71. - P. 4-12.
  27. Ritchlin C.T., Kavanaugh A., Gladman D.D., et al. Treatment recommendations for psoriatic arthritis // Ann. Rheum. Dis. - 2009. - Vol. 68. -P. 1387-94.
  28. McInnes I., Kavanaugh A., Gottlieb A., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebocontrolled PSUMMIT 1 trial. - Lancet 2013. [Epub ahead of print.]
  29. Kavanaugh A., Menter A., Mendelsohn A., et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebocontrolled, phase II trial//Curr. Med. Res. Opin. - 2010. - Vol. 26. - P. 2385-92.
  30. Gottlieb A., Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential // Ther. Adv. Musculoskelet. Dis. - 2013. - Vol. 5(5). - P. 277-85.
  31. Kristensen L.E., Gulfe A., Saxne T., et al. Eficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register// Ann. Rheum. Dis. - 2008. -Vol. 67. - P. 364-69.
  32. Saad A.A., Ashcroft D.M., Watson K.D., et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register// Rheumatology (Oxford). - 2010. -Vol. 49. - P. 697-705.
  33. Glintborg B., Ostergaard M., Dreyer L., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry// Arthritis Rheum. - 2011. -Vol. 63. - P. 382-90.
  34. Mease P. Update on Treatment of Psoriatic Arthritis //Bulletin of the NYU Hospital for Joint Diseases. - 2012. - Vol. 70(3). - P. 167-71.
  35. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study// Arthritis Rheum. - 2009. - Vol. 60. - P. 976-86.
  36. Van der Heijde D., Sieper J., Maksymowych W.P., et al. Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis // Ann. Rheum. Dis. - 2011. - Vol. 70. - P. 905-08.
  37. Coates L.C.,Cawkwell L.S.,Ng N.W.,Bennett A.N., Bryer D.J., Fraser A.D., et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life expe-rience // Ann. Rheum. Dis. - 2008. - Vol. 67. -P. 717-19.
  38. Heiberg M.S., Koldingsnes W., Mikkelsen K., et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study // Arthritis Rheum. - 2008. - Vol. 59. - P. 234-40.
  39. Thorlund K., Druyts E., Avina-Zubieta J., Mills E. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis // Biologics: Targets and Therapy. - 2012. - Vol. 6. -P. 417-27.
  40. Rozenblit M., Lebwohl M. New biologics for psoriasis and psoriatic arthritis // Dermatol. Ther. - 2009. - Vol. 22. - P. 56-60.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies